To investigate and analyze the adverse event (AE) signals associated with trastuzumab deruxtecan, and provide scientific basic for clinical use and regulatory decision-making.
AE reports related to trastuzumab deruxtecan from its market launch to Nov 24, 2024, were retrieved from the WHO-VigiAccess and FAERS databases. Disproportionality analysis methods, including reporting odds ratio, proportional reporting ratio, and Bayesian confidence propagation neural network, were used for signal detection.
A total of 12 545 reports from WHO-VigiAccess and 5 924 reports from the FAERS database related to trastuzumab deruxtecan were included. A total of 243 significant AE signals were identified, involving 20 system organ classification, with a focus on general disorders and administration site reactions, gastrointestinal disorders, respiratory, thoracic and mediastinal disorders, and blood and lymphatic system disorders. Additionally, 114 new potential risk signals were detected (accounting for 46.91%), including weight gain, ascites, pleural effusion, sepsis, pulmonary embolism, and PJP.
Continuous monitoring of drug safety is essential during trastuzumab deruxtecan therapy to maximize therapeutic outcomes and minimize risks.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |